Cargando…

Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study

BACKGROUND: The range of onset ages within some PSEN1 families is wide, and a few cases of reduced penetrance of PSEN1 mutations have been reported. However, published data on reduced penetrance have been limited to clinical histories, often collected retrospectively and lacking biomarker informatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thordardottir, Steinunn, Rodriguez-Vieitez, Elena, Almkvist, Ove, Ferreira, Daniel, Saint-Aubert, Laure, Kinhult-Ståhlbom, Anne, Thonberg, Håkan, Schöll, Michael, Westman, Eric, Wall, Anders, Eriksdotter, Maria, Zetterberg, Henrik, Blennow, Kaj, Nordberg, Agneta, Graff, Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5944151/ https://www.ncbi.nlm.nih.gov/pubmed/29747683 http://dx.doi.org/10.1186/s13195-018-0374-y

Ejemplares similares

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo
por: Thordardottir, Steinunn, et al.
Publicado: (2017)

Early astrocytosis in autosomal dominant Alzheimer’s disease measured in vivo by multi-tracer positron emission tomography
por: Schöll, Michael, et al.
Publicado: (2015)

Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease
por: Rodriguez-Vieitez, Elena, et al.
Publicado: (2016)

APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal‐dominant Alzheimer's disease
por: Almkvist, Ove, et al.
Publicado: (2022)

Cerebrospinal Fluid YKL-40 and Neurogranin in Familial Alzheimer’s Disease: A Pilot Study
por: Thordardottir, Steinunn, et al.
Publicado: (2020)

Plasma biomarker profiles in autosomal dominant Alzheimer’s disease
por: Johansson, Charlotte, et al.
Publicado: (2023)

Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease
por: Vilaplana, Eduard, et al.
Publicado: (2020)

The APOE ε4 Allele Affects Cognitive Functions Differently in Carriers of APP Mutations Compared to Carriers of PSEN1 Mutations in Autosomal-Dominant Alzheimer’s Disease
por: Almkvist, Ove, et al.
Publicado: (2021)

Plasma metabolomics of presymptomatic PSEN1‐H163Y mutation carriers: a pilot study
por: Natarajan, Karthick, et al.
Publicado: (2021)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Amyloid, tau, and astrocyte pathology in autosomal-dominant Alzheimer’s disease variants: AβPParc and PSEN1DE9
por: Lemoine, Laetitia, et al.
Publicado: (2020)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
por: Karami, Azadeh, et al.
Publicado: (2019)

Practice effects in cognitive assessments three years later in non-carriers but not in symptom-free mutation carriers of autosomal-dominant Alzheimer's disease: Exemplifying procedural learning and memory?
por: Almkvist, Ove, et al.
Publicado: (2022)

A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease
por: Almkvist, Ove, et al.
Publicado: (2023)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer’s disease
por: Carter, Stephen F., et al.
Publicado: (2018)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer’s disease patients: application of a second-generation encapsulated cell biodelivery device
por: Eyjolfsdottir, Helga, et al.
Publicado: (2016)

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer’s disease
por: Kadir, Ahmadul, et al.
Publicado: (2011)

Identification and description of three families with familial Alzheimer disease that segregate variants in the SORL1 gene
por: Thonberg, Håkan, et al.
Publicado: (2017)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease
por: Schultz, Stephanie A., et al.
Publicado: (2023)

Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families
por: Cruchaga, Carlos, et al.
Publicado: (2012)

Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2
por: Hsu, Simon, et al.
Publicado: (2020)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Circular RNA detection identifies circPSEN1 alterations in brain specific to autosomal dominant Alzheimer's disease
por: Chen, Hsiang-Han, et al.
Publicado: (2022)

Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer
por: Ståhlbom, Anne Kinhult, et al.
Publicado: (2011)

Correction: Rare Variants in APP, PSEN1 and PSEN2 Increase Risk for AD in Late-Onset Alzheimer's Disease Families
por: Cruchaga, Carlos, et al.
Publicado: (2012)

PSEN as an Educational Tool in Norway
por: Westvik, Tormod Schumacher
Publicado: (2017)

APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease
por: Giau, Vo Van, et al.
Publicado: (2019)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Association of Cerebrovascular and Alzheimer Disease Biomarkers With Cholinergic White Matter Degeneration in Cognitively Unimpaired Individuals
por: Cedres, Nira, et al.
Publicado: (2022)

Growth differentiation factor 15 increases in both cerebrospinal fluid and serum during pregnancy
por: Andersson-Hall, Ulrika, et al.
Publicado: (2021)

Amyloid-β(1–43) cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations
por: Perrone, Federica, et al.
Publicado: (2020)

From EST to structure models for functional inference of APP, BACE1, PSEN1, PSEN2 genes
por: Aathi, Muthusankar, et al.
Publicado: (2019)

APP, PSEN1, and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines
por: Xiao, Xuewen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqika6b3luk4qmaa9hraeor5pu